These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 37431986)

  • 1. NAFLD: An Emerging Causal Factor for Cardiovascular Disease.
    Li M; Wang H; Zhang XJ; Cai J; Li H
    Physiology (Bethesda); 2023 Nov; 38(6):0. PubMed ID: 37431986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases.
    Cai J; Zhang XJ; Ji YX; Zhang P; She ZG; Li H
    Circ Res; 2020 Feb; 126(5):679-704. PubMed ID: 32105577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter.
    Chiriac S; Stanciu C; Girleanu I; Cojocariu C; Sfarti C; Singeap AM; Cuciureanu T; Huiban L; Muzica CM; Zenovia S; Nastasa R; Trifan A
    Can J Gastroenterol Hepatol; 2021; 2021():6696857. PubMed ID: 33505944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk.
    Caussy C; Aubin A; Loomba R
    Curr Diab Rep; 2021 Mar; 21(5):15. PubMed ID: 33742318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease.
    Luo J; Xu L; Li J; Zhao S
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):193-9. PubMed ID: 25563143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.
    Muzurović E; Mikhailidis DP; Mantzoros C
    Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors.
    Muzurović E; Peng CC; Belanger MJ; Sanoudou D; Mikhailidis DP; Mantzoros CS
    Hypertension; 2022 Jul; 79(7):1319-1326. PubMed ID: 35465684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease (NAFLD)-A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients.
    Mikolasevic I; Milic S; Racki S; Zaputovic L; Stimac D; Radic M; Markic D; Orlic L
    Perit Dial Int; 2016; 36(4):427-32. PubMed ID: 26475841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance.
    Fiorentino TV; Succurro E; Sciacqua A; Andreozzi F; Perticone F; Sesti G
    Diabetes Metab Res Rev; 2020 Nov; 36(8):e3333. PubMed ID: 32356922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
    Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
    Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review.
    Stahl EP; Dhindsa DS; Lee SK; Sandesara PB; Chalasani NP; Sperling LS
    J Am Coll Cardiol; 2019 Mar; 73(8):948-963. PubMed ID: 30819364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease.
    Wang B; Zhao Z; Liu S; Wang S; Chen Y; Xu Y; Xu M; Wang W; Ning G; Li M; Wang T; Bi Y
    Diabetes Res Clin Pract; 2021 Jul; 177():108873. PubMed ID: 34051282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risk: Is Imaging Helpful?
    Doumas SA; Tripathi S; Kashikar A; Khuttan A; Kumar A; Singh H; Canakis JP; Ashish K; Dey D; Oppenheim I; Dey AK
    Curr Probl Cardiol; 2024 Jan; 49(1 Pt B):102065. PubMed ID: 37652112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAFLD and cardiovascular diseases: a clinical review.
    Kasper P; Martin A; Lang S; Kütting F; Goeser T; Demir M; Steffen HM
    Clin Res Cardiol; 2021 Jul; 110(7):921-937. PubMed ID: 32696080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NAFLD: a multisystem disease.
    Byrne CD; Targher G
    J Hepatol; 2015 Apr; 62(1 Suppl):S47-64. PubMed ID: 25920090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease.
    Corey KE; Chalasani N
    Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1077-84; quiz e59-60. PubMed ID: 23962548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?
    Ahmed MH; Barakat S; Almobarak AO
    J Obes; 2012; 2012():483135. PubMed ID: 23320150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.